ATE253051T1 - Chinolinderivate und chinazolinderivate - Google Patents

Chinolinderivate und chinazolinderivate

Info

Publication number: ATE253051T1
Authority: AT; Austria
Prior art keywords: represent; derivatives; alkyl; alkoxy; compounds
Prior art date: 1999-01-22

Application number

AT00900841T

Other languages

English (en)

Inventor

Kazuo Kubo

Yasunari Fujiwara

Toshiyuki Isoe

Original Assignee

Kirin Brewery

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-22

Filing date

2000-01-20

Publication date

2003-11-15

2000-01-20 Application filed by Kirin Brewery filed Critical Kirin Brewery

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE253051T1 publication Critical patent/ATE253051T1/de

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000005415 substituted alkoxy group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Pyrane Compounds (AREA)

AT00900841T 1999-01-22 2000-01-20 Chinolinderivate und chinazolinderivate ATE253051T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP1485899		1999-01-22
JP2669199		1999-02-03
JP14249399		1999-05-21
JP25362499		1999-09-07
PCT/JP2000/000255 WO2000043366A1 (en)	1999-01-22	2000-01-20	Quinoline derivatives and quinazoline derivatives

Publications (1)

Publication Number	Publication Date
ATE253051T1 true ATE253051T1 (de)	2003-11-15

Family

ID=27456291

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03024911T ATE356117T1 (de)	1999-01-22	2000-01-20	Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
AT00900841T ATE253051T1 (de)	1999-01-22	2000-01-20	Chinolinderivate und chinazolinderivate

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03024911T ATE356117T1 (de)	1999-01-22	2000-01-20	Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität

Country Status (19)

Country	Link
US (3)	US6797823B1 (de)
EP (2)	EP1153920B1 (de)
JP (2)	JP3519368B2 (de)
KR (1)	KR100787254B1 (de)
CN (1)	CN1183114C (de)
AT (2)	ATE356117T1 (de)
AU (1)	AU771504B2 (de)
BR (1)	BR0007656A (de)
CA (1)	CA2361057C (de)
DE (2)	DE60033857T2 (de)
ES (2)	ES2281591T3 (de)
HU (1)	HU230789B1 (de)
IL (2)	IL144461A0 (de)
NO (1)	NO321295B1 (de)
NZ (1)	NZ513006A (de)
PL (2)	PL206627B1 (de)
TR (1)	TR200102090T2 (de)
TW (1)	TWI229667B (de)
WO (1)	WO2000043366A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7329670B1 (en)	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en)	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ATE538794T1 (de)	1999-01-13	2012-01-15	Bayer Healthcare Llc	Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) *	1999-01-13	2000-07-20	Bayer Corporation	φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
IL144461A0 (en) *	1999-01-22	2002-05-23	Kirin Brewery	Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
EP1243582A4 (de) *	1999-12-24	2003-06-04	Kirin Brewery	Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten
DE60137273D1 (de)	2000-10-20	2009-02-12	Eisai R&D Man Co Ltd	Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
GB0029015D0 (en)	2000-11-28	2001-01-10	Univ London	Medical device
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en)	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1652847B1 (de) *	2001-04-27	2008-05-28	Kirin Pharma Kabushiki Kaisha	Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
EP2258366B1 (de) *	2001-06-22	2013-04-03	Kirin Pharma Kabushiki Kaisha	Zur Hemmung der Autophosphorylierung von Hepazotyten-Wachstumsfaktorrezeptoren fähige Chinolinderivate und diese enthaltende pharmazeutische Zusammensetzungen
JPWO2003008388A1 (ja) *	2001-07-19	2004-11-11	麒麟麦酒株式会社	Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キナゾリニル）オキシ］フェニル｝−ｎ’−プロピルウレアのｉ型結晶およびその製造法
EP1447405A4 (de) *	2001-10-17	2005-01-12	Kirin Brewery	Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen
JP4608215B2 (ja)	2002-02-01	2011-01-12	アストラゼネカアクチボラグ	キナゾリン化合物
WO2003068229A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007832A (es)	2002-02-11	2005-09-08	Bayer Pharmaceuticals Corp	Aril-ureas con actividad inhibitoria de angiogenesis.
MXPA04007830A (es)	2002-02-11	2005-07-01	Bayer Pharmaceuticals Corp	Arilureas como inhibidores de cinasa.
EP1535910A4 (de) *	2002-05-01	2007-03-14	Kirin Brewery	Chinolinderivate und chinazolinderivate, die die autophosphorilierung des macrophage colony stimulating factor receptors inhibieren
US7202244B2 (en)	2002-05-29	2007-04-10	Millennium Pharmaceuticals, Inc.	Chk-1 inhibitors
EP2280003B1 (de)	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
AU2003280599A1 (en) *	2002-10-29	2004-05-25	Kirin Beer Kabushiki Kaisha	QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US7557129B2 (en)	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE508747T1 (de) *	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
WO2004113274A2 (en)	2003-05-20	2004-12-29	Bayer Pharmaceuticals Corporation	Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru)	2003-07-23	2008-10-30	Байер Фамэсьютиклс Копэрейшн	Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
AU2013204031B2 (en) *	2003-09-26	2016-10-27	Exelixis, Inc.	c-Met modulators and methods of use
PT2213661E (pt)	2003-09-26	2011-12-15	Exelixis Inc	Moduladores de c-met e métodos de uso
US7683172B2 (en)	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
US20070270589A1 (en) *	2003-11-28	2007-11-22	Mitsubishi Pharma Corporation	Quinazoline Derivative and Process for Producing the Same
EA009994B1 (ru) *	2003-12-23	2008-06-30	Пфайзер Инк.	Новые хинолиновые производные
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
CN101010315A (zh)	2004-04-30	2007-08-01	拜耳制药公司	用于治疗癌症的取代的吡唑基脲衍生物
US7173031B2 (en)	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US8426429B2 (en)	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
AU2005283422C1 (en)	2004-09-17	2017-02-02	Eisai R & D Management Co., Ltd.	Medicinal composition
MX2007006230A (es) *	2004-11-30	2007-07-25	Amgen Inc	Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
SG160364A1 (en) *	2005-03-07	2010-04-29	Bayer Schering Pharma Ag	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
JO2787B1 (en) *	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
TW200740820A (en) *	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
EP1925941B1 (de) *	2005-08-01	2012-11-28	Eisai R&D Management Co., Ltd.	Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
WO2007015578A1 (ja)	2005-08-02	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を検定する方法
CA2620594C (en) *	2005-09-01	2012-08-21	Eisai R&D Management Co., Ltd.	Pharmaceutical composition having improved disintegratability
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
CN101316590B (zh) *	2005-11-07	2011-08-03	卫材R&D管理有限公司	血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007061130A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
US7776882B2 (en) *	2006-02-06	2010-08-17	Baxter Ellen W	2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) *	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
WO2007092854A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
RU2448708C3 (ru) *	2006-05-18	2017-09-28	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство против рака щитовидной железы
EP2044939A1 (de) *	2006-06-29	2009-04-08	Eisai R&D Management Co., Ltd.	Therapeutisches mittel gegen leberfibrose
PE20080538A1 (es)	2006-08-04	2008-06-18	Takeda Pharmaceutical	Derivado heterociclico fusionado y su uso
WO2008020302A2 (en) *	2006-08-17	2008-02-21	Pfizer Products Inc.	Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
CN101511793B (zh) *	2006-08-28	2011-08-03	卫材R&D管理有限公司	针对未分化型胃癌的抗肿瘤剂
WO2008044688A1 (en) *	2006-10-11	2008-04-17	Daiichi Sankyo Company, Limited	Urea derivative
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JPWO2008087736A1 (ja) *	2007-01-19	2010-05-06	宇部興産株式会社	アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
CN101600694A (zh)	2007-01-29	2009-12-09	卫材R&D管理有限公司	未分化型胃癌治疗用组合物
US8557853B2 (en) *	2007-02-09	2013-10-15	Allergan, Inc.	Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents
CL2008001626A1 (es)	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
EP2181987B9 (de) *	2007-08-23	2014-09-03	Takeda Pharmaceutical Company Limited	2-Carbonylaminobenzothiazole und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2008337286B2 (en) *	2007-12-19	2014-08-07	Cancer Research Technology Limited	Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
ES2385118T3 (es) *	2008-01-17	2012-07-18	Bayer Pharma Aktiengesellschaft	Derivados de quinazolina sustituida con sulfoximina como inmunomoduladores, su preparación y uso como medicamentos
US8076358B2 (en) *	2008-01-28	2011-12-13	Janssen Pharmaceutica Nv	6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
ES2397682T3 (es) *	2008-01-29	2013-03-08	Janssen Pharmaceutica Nv	Derivados de 2-amino-quinolina útiles como inhibidores de la beta-secretasa (BACE)
AU2009210098B2 (en) *	2008-01-29	2013-06-13	Eisai R & D Management Co., Ltd.	Combined use of angiogenesis inhibitor and taxane
SI2947072T1 (sl)	2008-03-17	2017-03-31	Ambit Biosciences Corporation	1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
EP2262772B8 (de) *	2008-04-16	2013-03-13	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Chinolinderivate als axl-kinase-inhibitoren
EP2340244A4 (de) *	2008-10-14	2012-07-25	Ning Xi	Verbindungen und anwendungsverfahren
US8697874B2 (en) *	2008-12-01	2014-04-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
JO3101B1 (ar)	2008-12-02	2017-09-20	Takeda Pharmaceuticals Co	مشتقات بنزوثيازول كعوامل مضادة للسرطان
SG173014A1 (en)	2009-01-16	2011-08-29	Exelixis Inc	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
ES2578990T3 (es) *	2009-03-21	2016-08-03	Sunshine Lake Pharma Co., Ltd.	Derivados de amino éster, sales de los mismos y métodos de uso
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
CN101671301B (zh) *	2009-05-05	2014-02-26	江苏省药物研究所有限公司	杂环取代的二苯脲类衍生物及其用途
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
DK2468281T3 (en)	2009-08-19	2016-03-21	Eisai R&D Man Co Ltd	Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja)	2010-06-25	2011-12-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
KR20130091331A (ko)	2010-07-16	2013-08-16	교와 핫꼬 기린 가부시키가이샤	함질소 방향족 복소환 유도체
JP2014505109A (ja)	2011-02-10	2014-02-27	エクセリクシス，インク．	キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
CN103402519B (zh)	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102311395B (zh) *	2011-07-05	2014-04-16	张爱华	喹唑啉环取代的二苯脲类衍生物及其用途
CN102432595B (zh) *	2011-09-14	2013-09-25	湖南有色凯铂生物药业有限公司	N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
CN102408418A (zh) *	2011-10-21	2012-04-11	武汉迈德森医药科技有限公司	Tivozanib酸性盐及其制备方法和晶型
EP2780338B1 (de)	2011-11-14	2016-11-09	Ignyta, Inc.	Uracilderivate als axl- und c-met-kinaseinhibitoren
CN102603718B (zh) *	2012-02-08	2014-01-29	武汉凯斯瑞科技有限公司	西地尼布的合成方法
EP2626073A1 (de)	2012-02-13	2013-08-14	Harmonic Pharma	Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung
AU2013364953A1 (en)	2012-12-21	2015-04-30	Eisai R&D Management Co., Ltd.	Amorphous form of quinoline derivative, and method for producing same
WO2014127335A1 (en) *	2013-02-15	2014-08-21	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
JP6669499B2 (ja)	2013-02-15	2020-03-18	カラファーマシューティカルズインコーポレイテッド	治療用化合物
EP2997377B1 (de)	2013-05-14	2018-07-18	Eisai R&D Management Co., Ltd.	Biomarker zur vorhersage und beurteilung der reaktion von endometriumkarzinompatienten auf lenvatinibverbindungen
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en)	2015-02-25	2021-06-03	Eisai R&D Management Co., Ltd.	Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt)	2015-06-16	2023-12-12	Eisai R&D Management Co., Ltd	Agente anti-câncer
JP6553726B2 (ja)	2015-08-20	2019-07-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
KR20180086187A (ko)	2015-10-05	2018-07-30	더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕	자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
CN106496116A (zh) *	2016-10-21	2017-03-15	沈阳药科大学	含双芳基脲结构的喹啉类化合物及其用途
EP3548007A4 (de)	2016-12-01	2020-08-12	Ignyta, Inc.	Verfahren zur behandlung von krebs
CN108239067A (zh) *	2016-12-27	2018-07-03	沈阳药科大学	喹唑啉酮类衍生物及其制备方法和用途
JP6581320B2 (ja)	2017-02-08	2019-09-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療用医薬組成物
EP3624800A4 (de)	2017-05-16	2021-02-17	Eisai R&D Management Co., Ltd.	Behandlung von leberzellkarzinom
CN109824587A (zh) *	2017-11-23	2019-05-31	上海翔锦生物科技有限公司	酪氨酸激酶抑制剂xjf007及其中间体的制备方法
CN109553581B (zh) *	2018-09-25	2022-01-25	广州六顺生物科技股份有限公司	取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
CN111303024B (zh) *	2018-12-12	2023-03-28	安徽中科拓苒药物科学研究有限公司	一种喹啉结构的pan-KIT激酶抑制剂及其用途
JP2020100598A (ja)	2018-12-25	2020-07-02	公益財団法人応用生化学研究所	レンバチニブ誘導体、並びにそれを用いた医薬研究用組成物及び腫瘍治療剤
WO2021144360A1 (en)	2020-01-17	2021-07-22	F. Hoffmann-La Roche Ag	Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
CN113620873B (zh) *	2020-05-07	2023-12-08	沈阳药科大学	含锌结合基以及喹啉骨架的化合物的制备方法和用途
CN116763787A (zh) *	2022-03-08	2023-09-19	安徽中科拓苒药物科学研究有限公司	喹啉类化合物的新用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP2783722B2 (ja) *	1991-07-12	1998-08-06	麒麟麦酒株式会社	スピカマイシン誘導体およびそれを含む抗腫瘍剤
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
CN1158599A (zh) *	1994-09-20	1997-09-03	住友金属工业株式会社	介质陶瓷组成物及其制造方法
US6143764A (en) *	1995-11-07	2000-11-07	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
JP4194678B2 (ja)	1997-11-28	2008-12-10	キリンファーマ株式会社	キノリン誘導体およびそれを含む医薬組成物
IL144461A0 (en) *	1999-01-22	2002-05-23	Kirin Brewery	Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
EP1243582A4 (de) *	1999-12-24	2003-06-04	Kirin Brewery	Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten
EP1652847B1 (de) *	2001-04-27	2008-05-28	Kirin Pharma Kabushiki Kaisha	Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
EP1447405A4 (de) *	2001-10-17	2005-01-12	Kirin Brewery	Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen
EP1535910A4 (de) *	2002-05-01	2007-03-14	Kirin Brewery	Chinolinderivate und chinazolinderivate, die die autophosphorilierung des macrophage colony stimulating factor receptors inhibieren
JP3763414B2 (ja) *	2002-10-21	2006-04-05	麒麟麦酒株式会社	Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
AU2003280599A1 (en) *	2002-10-29	2004-05-25	Kirin Beer Kabushiki Kaisha	QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US20040229676A1 (en) *	2003-04-28	2004-11-18	Gerald Duhamel	Method of playing a game of chance

2000
- 2000-01-20 IL IL14446100A patent/IL144461A0/xx active IP Right Grant
- 2000-01-20 EP EP00900841A patent/EP1153920B1/de not_active Expired - Lifetime
- 2000-01-20 DE DE60033857T patent/DE60033857T2/de not_active Expired - Lifetime
- 2000-01-20 BR BR0007656-2A patent/BR0007656A/pt active Search and Examination
- 2000-01-20 HU HU0105133A patent/HU230789B1/hu unknown
- 2000-01-20 PL PL388667A patent/PL206627B1/pl not_active IP Right Cessation
- 2000-01-20 EP EP03024911A patent/EP1384712B1/de not_active Expired - Lifetime
- 2000-01-20 NZ NZ513006A patent/NZ513006A/en not_active IP Right Cessation
- 2000-01-20 DE DE60006216T patent/DE60006216T2/de not_active Expired - Lifetime
- 2000-01-20 ES ES03024911T patent/ES2281591T3/es not_active Expired - Lifetime
- 2000-01-20 PL PL349036A patent/PL204856B1/pl not_active IP Right Cessation
- 2000-01-20 WO PCT/JP2000/000255 patent/WO2000043366A1/ja not_active Ceased
- 2000-01-20 CA CA2361057A patent/CA2361057C/en not_active Expired - Fee Related
- 2000-01-20 CN CNB008054282A patent/CN1183114C/zh not_active Expired - Fee Related
- 2000-01-20 AT AT03024911T patent/ATE356117T1/de not_active IP Right Cessation
- 2000-01-20 AT AT00900841T patent/ATE253051T1/de not_active IP Right Cessation
- 2000-01-20 JP JP2000594782A patent/JP3519368B2/ja not_active Expired - Fee Related
- 2000-01-20 AU AU30748/00A patent/AU771504B2/en not_active Ceased
- 2000-01-20 TR TR2001/02090T patent/TR200102090T2/xx unknown
- 2000-01-20 KR KR1020017009144A patent/KR100787254B1/ko not_active Expired - Fee Related
- 2000-01-20 ES ES00900841T patent/ES2208261T3/es not_active Expired - Lifetime
- 2000-01-20 US US09/889,858 patent/US6797823B1/en not_active Expired - Fee Related
- 2000-01-21 TW TW089100998A patent/TWI229667B/zh not_active IP Right Cessation
2001
- 2001-05-29 NO NO20012617A patent/NO321295B1/no not_active IP Right Cessation
- 2001-07-19 IL IL144461A patent/IL144461A/en not_active IP Right Cessation
2003
- 2003-05-06 JP JP2003128216A patent/JP2003286263A/ja not_active Withdrawn
2004
- 2004-05-10 US US10/842,009 patent/US7169789B2/en not_active Expired - Fee Related
2006
- 2006-09-26 US US11/526,739 patent/US20070027318A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1183114C (zh)	2005-01-05
NO20012617D0 (no)	2001-05-29
NO20012617L (no)	2001-09-14
IL144461A0 (en)	2002-05-23
US6797823B1 (en)	2004-09-28
WO2000043366A1 (en)	2000-07-27
HUP0105133A3 (en)	2002-09-30
HUP0105133A2 (hu)	2002-07-29
EP1153920A1 (de)	2001-11-14
ATE356117T1 (de)	2007-03-15
TWI229667B (en)	2005-03-21
ES2208261T3 (es)	2004-06-16
HU230789B1 (en)	2018-05-02
DE60033857D1 (de)	2007-04-19
TR200102090T2 (tr)	2002-01-21
ES2281591T3 (es)	2007-10-01
US7169789B2 (en)	2007-01-30
KR20010101857A (ko)	2001-11-15
PL349036A1 (en)	2002-07-01
AU3074800A (en)	2000-08-07
NZ513006A (en)	2003-10-31
CA2361057A1 (en)	2000-07-27
JP2003286263A (ja)	2003-10-10
HK1043792A1 (en)	2002-09-27
JP3519368B2 (ja)	2004-04-12
PL204856B1 (pl)	2010-02-26
EP1384712B1 (de)	2007-03-07
CA2361057C (en)	2010-04-06
EP1153920A4 (de)	2002-04-17
IL144461A (en)	2007-07-04
BR0007656A (pt)	2001-10-30
DE60006216D1 (de)	2003-12-04
KR100787254B1 (ko)	2007-12-20
US20040209905A1 (en)	2004-10-21
US20070027318A1 (en)	2007-02-01
AU771504B2 (en)	2004-03-25
EP1384712A1 (de)	2004-01-28
PL206627B1 (pl)	2010-09-30
DE60006216T2 (de)	2004-07-15
CN1344254A (zh)	2002-04-10
DE60033857T2 (de)	2007-10-25
EP1153920B1 (de)	2003-10-29
NO321295B1 (no)	2006-04-18

Legal Events

Date	Code	Title	Description
2004-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE253051T1 (de)	2003-11-15	Chinolinderivate und chinazolinderivate
BRPI0209216B8 (pt)	2021-05-25	derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
DE69418704D1 (de)	1999-07-01	Anthranilsäure derivate
CY1111816T1 (el)	2015-10-07	Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
AU2492500A (en)	2000-07-24	Aspartic protease inhibitors, compositions, and associated therapeutic methods
BR0210746A (pt)	2004-07-20	Derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina tendo atividade antiviral
DE60016384D1 (de)	2005-01-05	Chondrogonese promotoren und indolin-2-on derivate
DE60237652D1 (de)	2010-10-21	Variolinderivate und ihre Verwendung als Cytostatika
BR0108448A (pt)	2003-04-01	Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor
DE60230924D1 (de)	2009-03-05	2-substituierte vitamin-d-derivate